Eledon Pharmaceuticals Inc. held its Annual Meeting of Stockholders on June 10, 2025. The stockholders approved the election of Keith A. Katkin, Allan D. Kirk, M.D., Ph.D., FACS, and John S. McBride as Class II Directors. An amendment to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000 shares was approved. An amendment to the Certificate of Incorporation to provide exculpation for certain officers was also approved. Additionally, the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。